Publications by authors named "Melvin Morganroth"
Objectives: Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess whether performance improvement interventions could enhance COPD care and reduce exacerbations in primary care settings.
- An intervention was conducted in 12 clinics, with one group receiving enhanced support (education, case management, decision support) while the control group did not, and data on 242 patients was analyzed over a year.
- Despite no significant differences in exacerbation rates between intervention and control clinics, overall patient outcomes improved, showing a noteworthy reduction in exacerbation rates and related emergency visits across all clinics.